Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers

作     者：Ziqi Wan Yang Chen Junling Zhuang Miao Chen Shuyang Zhang Bing Han 

作者机构：Department of HematologyPeking Union Medical College HospitalChinese Academy of Medical ScienceBeijing 100730China Eight-Year Program of Clinical MedicineM.D.ProgramDepartment of Clinical MedicinePeking Union Medical CollegeBeijing 100005China Department of CardiologyPeking Union Medical College HospitalChinese Academy of Medical ScienceBeijing 100730China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第9期

页      面：1120-1122页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100214[医学-肿瘤学] 10[医学] 

基　　金：Chinese Acadmy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS 2021-1-I2M-003) PUMCH National High-Level Hospital Clinical Research Funding(Nos.2022-PUMCH-C-026,2022-PUMCH-D-002,2022-PUMCH-B-046) 

主　　题：anemia chemotherapy cyclosporin 

摘      要：To the Editor:Myelosuppression is one of the most common side effects of *** patients would develop long-lasting aplastic anemia(AA)even after stopping chemotherapy for over three months,due to persistent destruction of the bone *** a thrombopoietin-receptor agonist,eltrombopag(EPAG)has been widely used in patients with thrombocytopenia from various origins,[1]including those with AA secondary to ***,both EPAG and cyclosporin A(CsA)have been reported to possibly induce the expansion of abnormal clones or controversially increase the risk of neoplasms.[2]Thus,the challenge was to treat severe cytopenia while preventing cancer *** study reported the efficacy and safety of EPAG with or without CsA for patients with AA secondary to chemotherapy,in an attempt to find solutions to these difficulties.